

Shereen Abdel Alem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4125182/publications.pdf>

Version: 2024-02-01

31
papers

478
citations

1040056
9
h-index

677142
22
g-index

31
all docs

31
docs citations

31
times ranked

751
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV/HIV coinfecting Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 227-232.	1.8	3
2	Highly Sensitive Serum miRNA Panel for the Diagnosis of Hepatocellular Carcinoma in Egyptian Patients with HCV-Related HCC. Laboratory Medicine, 2022, 53, 523-529.	1.2	3
3	Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology, 2022, 76, E100-E100.	7.3	4
4	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies. Virus Research, 2022, 319, 198852.	2.2	3
5	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets, 2021, 32, 383-390.	2.3	5
6	Is Serum-Ascites Vitamin D Gradient a Valid Marker for Diagnosing Spontaneous Bacterial Peritonitis in Patients with Cirrhotic Ascites?. Laboratory Medicine, 2021, 52, 567-573.	1.2	1
7	Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. Journal of Hepatology, 2021, 74, 1261-1262.	3.7	28
8	Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals. Journal of Pediatrics, 2021, 233, 126-131.	1.8	8
9	Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study. Journal of Infection and Public Health, 2021, 14, 1466-1473.	4.1	9
10	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
11	Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1181-1189.	3.0	2
12	Is urinary β_2 -microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?. European Journal of Gastroenterology and Hepatology, 2021, 33, e992-e998.	1.6	3
13	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	1.8	0
14	Serum progranulin levels in paediatric patients with Gaucher disease; relation to disease severity and liver stiffness by transient elastography. Liver International, 2020, 40, 3051-3060.	3.9	1
15	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection, 2020, 48, 913-922.	4.7	2
16	Analysis of clinical and virologic features in Hepatitis B e Antigen (HBeAg)-negative and HBeAg-positive Egyptian chronic Hepatitis B patients. African Health Sciences, 2020, 20, 649-655.	0.7	4
17	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfecting patients with HCV genotype 4 infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 232-240.	1.8	5
18	Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, 1588-1594.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1009-1016.	3.0	5
20	Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. Journal of Interferon and Cytokine Research, 2019, 39, 780-785.	1.2	7
21	DAA's therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. Expert Review of Gastroenterology and Hepatology, 2019, 13, 693-698.	3.0	8
22	Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdominal Radiology, 2019, 44, 2751-2758.	2.1	12
23	Clinical impact of serum α -fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2019, 31, 1129-1134.	1.6	13
24	Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. Journal of Medical Virology, 2018, 90, 1508-1515.	5.0	8
25	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. European Journal of Gastroenterology and Hepatology, 2018, 30, 882-887.	1.6	6
26	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1624-1630.	2.8	71
27	Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. Journal of Medical Virology, 2017, 89, 2181-2187.	5.0	39
28	Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. Journal of Diabetes and Its Complications, 2017, 31, 186-194.	2.3	14
29	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology, 2016, 17, 78-83.	0.9	25
30	Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Research and Therapy, 2014, 5, 70.	5.5	98
31	Autologous CD34 ⁺ and CD133 ⁺ stem cells transplantation in patients with end stage liver disease. World Journal of Gastroenterology, 2010, 16, 5297.	3.3	85